Understanding of ROS-Inducing Strategy in Anticancer Therapy.

Kim SJ, Kim HS, Seo YR. · 2019

Read Understanding of ROS-Inducing Strategy in Anticancer Therapy. by Kim SJ, Kim HS, Seo YR. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6939418.txt.

Description

Kim and co-authors review a cancer strategy that floods tumour cells with reactive oxygen. Their review appeared in Oxidative Medicine and Cellular Longevity. Healthy redox balance keeps cells working properly. Cancer cells carry higher levels of reactive oxygen species, called ROS, yet survive through strong antioxidant defences.

Therapies that push ROS higher, or block those defences, can break that balance. The overload then damages cancer cells severely. The authors examine several pro-oxidant drugs, including cisplatin, doxorubicin, and imexon. Using pathway analysis and large-scale text mining, they map how each drug interacts with genes, cell processes, and disease. They also note side effects. Genetic studies, they argue, are still needed to sharpen selective killing.

Catalog record

CREATORKim SJ, Kim HS, Seo YR.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6939418

Browse the full library · About the Tower of Babel